Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AffyXell Therapeutics
Avacta Pursues Combination Therapy Approach Targeting Solid Tumors
Avacta CEO Alastair Smith talks to In Vivo about the company’s precision chemistry, immunotherapy and diagnostic programs.
Avacta/Daewoong’s Joint-Venture AffyXell Paves Way For Next-Generation Stem Cell Therapy
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.
- Gene Therapy, Cell Therapy
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.